PMID- 22119746
OWN - NLM
STAT- MEDLINE
DCOM- 20120508
LR  - 20221207
IS  - 1878-4216 (Electronic)
IS  - 0278-5846 (Linking)
VI  - 36
IP  - 2
DP  - 2012 Mar 30
TI  - Effect of olanzapine orally disintegrating tablet versus oral standard tablet on 
      body weight in patients with schizophrenia: a randomized open-label trial.
PG  - 313-7
LID - 10.1016/j.pnpbp.2011.11.004 [doi]
AB  - Olanzapine has frequently been reported to induce substantial weight gain, which 
      is associated with an increased prevalence of dyslipidemia and type 2 diabetes. 
      Several reports have described that olanzapine orally disintegrating tablets 
      (ODT) induce less weight gain than oral standard tablets (OST) do, although both 
      forms have equal bioavailability. We tried to clarify whether or not body weight 
      change differed between olanzapine ODT and OST treatments in olanzapine-naive 
      schizophrenia patients. An open-label, 12-month, multicenter, randomized, 
      flexible-dose study was conducted for direct comparison of the effects of OST 
      (mean dosage, 15.7 mg; N=57) and ODT (mean dosage, 15.2 mg; N=61) on body weight 
      and metabolic measures such as blood glucose, hemoglobin(A1c), total cholesterol 
      and HDL-cholesterol, and triglycerides in olanzapine-naive patients with 
      schizophrenia. Outcome measures included Positive and Negative Syndrome Scale 
      (PANSS), Global Assessment of Function (GAF), The World Health Organization 
      Quality of Life 26 (WHO-QOL26), Drug Attitude Inventory (DAI)-10, and 
      tolerability assessed by the UKU side-effect rating scale. This study was 
      conducted between June 2007 and April 2010. No significant difference was found 
      in the weight gain between the two forms of olanzapine. No significant difference 
      was found between the two groups in any metabolic measure, efficacy, 
      tolerability, WHO-QOL26, or DAI-10 score. Previous reports describing that 
      olanzapine ODT induced less weight gain than OST were not supported by results of 
      this randomized study.
CI  - Copyright (c) 2011 Elsevier Inc. All rights reserved.
FAU - Kusumi, Ichiro
AU  - Kusumi I
AD  - Department of Psychiatry, Hokkaido University Graduate School of Medicine, 
      Sapporo, Japan. ikusumi@med.hokudai.ac.jp
FAU - Honda, Minoru
AU  - Honda M
FAU - Uemura, Keiichi
AU  - Uemura K
FAU - Sugawara, Yasuhumi
AU  - Sugawara Y
FAU - Kohsaka, Masako
AU  - Kohsaka M
FAU - Tochigi, Akihiko
AU  - Tochigi A
FAU - Koyama, Tsukasa
AU  - Koyama T
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20111115
PL  - England
TA  - Prog Neuropsychopharmacol Biol Psychiatry
JT  - Progress in neuro-psychopharmacology & biological psychiatry
JID - 8211617
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Tablets)
RN  - 0 (Triglycerides)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 12794-10-4 (Benzodiazepines)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - N7U69T4SZR (Olanzapine)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Benzodiazepines/*administration & dosage/*adverse effects/therapeutic use
MH  - Blood Glucose
MH  - Body Weight/drug effects
MH  - Cholesterol/blood
MH  - Female
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Olanzapine
MH  - Psychiatric Status Rating Scales/statistics & numerical data
MH  - Quality of Life/*psychology
MH  - Schizophrenia/*drug therapy/metabolism
MH  - *Schizophrenic Psychology
MH  - Tablets/therapeutic use
MH  - Triglycerides/blood
EDAT- 2011/11/29 06:00
MHDA- 2012/05/09 06:00
CRDT- 2011/11/29 06:00
PHST- 2011/09/26 00:00 [received]
PHST- 2011/11/09 00:00 [revised]
PHST- 2011/11/10 00:00 [accepted]
PHST- 2011/11/29 06:00 [entrez]
PHST- 2011/11/29 06:00 [pubmed]
PHST- 2012/05/09 06:00 [medline]
AID - S0278-5846(11)00319-8 [pii]
AID - 10.1016/j.pnpbp.2011.11.004 [doi]
PST - ppublish
SO  - Prog Neuropsychopharmacol Biol Psychiatry. 2012 Mar 30;36(2):313-7. doi: 
      10.1016/j.pnpbp.2011.11.004. Epub 2011 Nov 15.